Clinical outcomes and patterns of failure of head and neck mucosal melanoma treated with multiple treatment modalities

The study aims to analyze the clinical characteristics of head and neck mucosal melanoma (MMHN) and the effects of multiple treatment modalities on distant metastasis, recurrence and survival rates to provide a reference for the individualized treatment of MMHN. We retrospectively reviewed 262 patie...

Full description

Saved in:
Bibliographic Details
Published in:Radiation oncology (London, England) England), 2021-07, Vol.16 (1), p.138-138, Article 138
Main Authors: Xu, Qing-Qing, Lai, Yan-Zhen, Huang, Zi-Lu, Zeng, Zi-Yi, Zhang, Ya-Ni, Ou, Rui-Yao, Wu, Wen-Min, Chen, Lei, Lu, Li-Xia
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Cancer
Care and treatment
Chemotherapy
Classification
Clinical outcome
Clinical outcomes
Combined Modality Therapy
Female
Follow-Up Studies
Head and neck
Head and neck cancer
Head and neck mucosal melanoma
Head and Neck Neoplasms - mortality
Head and Neck Neoplasms - pathology
Head and Neck Neoplasms - therapy
Health services
Humans
Immunologic/targeted therapy
Irradiation
Larynx
Male
Medical prognosis
Melanoma
Melanoma - mortality
Melanoma - pathology
Melanoma - therapy
Metastases
Metastasis
Methods
Middle Aged
Mucosa
Mucous Membrane - pathology
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - therapy
Patient outcomes
Patients
Prognosis
Radiation therapy
Radiotherapy
Regression analysis
Retrospective Studies
Surgery
Survival
Survival Rate
Treatment Failure
Treatment modalities
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study aims to analyze the clinical characteristics of head and neck mucosal melanoma (MMHN) and the effects of multiple treatment modalities on distant metastasis, recurrence and survival rates to provide a reference for the individualized treatment of MMHN. We retrospectively reviewed 262 patients with stage III-IVb MMHN treated from March 1986 to November 2018 at our cancer center. The median follow-up time was 34.0 months (range 1-262 months). The 5-year overall survival (OS), distant metastasis-free survival (DMFS) and disease-free survival (DFS) probabilities were 37.7%, 30.2%, and 20.3%, respectively. The 5-year OS rates for patients with stage III, stage IVA, and stage IVB MMHN were 67.0%, 24.1% and 8.3%, respectively (P 
ISSN:1748-717X
1748-717X
DOI:10.1186/s13014-021-01860-z